PM Stock Analysis — Philip Morris International
Sector: Consumer staples
AI Verdict
PM trades at 20.5x next year's earnings with nearly 29% expected EPS growth—cheap for the growth if IQOS keeps its regulatory and patent edge, but any stumble could erase the premium.
Competitive Moat
Philip Morris owns the global rights to Marlboro and a portfolio of leading tobacco brands, giving it pricing power and entrenched distribution networks in regulated markets. Its IQOS heated tobacco system is protected by patents and regulatory approvals, making it hard for rivals to compete directly in the reduced-risk product segment.
Summary
PM's shift to smoke-free products like IQOS is driving a forecasted 28.8% jump in earnings next year.
Where It Stands
The stock has a 1-year return of 5.11%, an RSI of 54.1 (neutral), and trades at 20.5x forward earnings versus the consumer staples median of 20x.
Key Metrics
- RSI: 54.1 — Neutral
- Trailing P/E: 26.3x
- Forward P/E: 20.5x
- PEG Ratio: 0.90
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- Market Cap: $291.6B
- Dividend Yield: 0.03%
- 1-Year Return: 5.11%
- 52-Week High: $193.05
- 52-Week Low: $142.11
Analyst Consensus
19 Buy · 7 Hold · 0 Sell (26 analysts)
Bull Case
Forward EPS growth of 28.8% justifies paying a slight premium to the sector median P/E, especially with IQOS's patent moat.
Bear Case
If the forward P/E compresses from 20.5x to the sector median of 20x, shares could lose about 2.5% even if earnings meet expectations.
Catalyst to Watch
Watch for regulatory decisions and IQOS adoption rates, as any setback in smoke-free product momentum could derail the growth outlook.